- Covovax is the ninth vaccine approved in the Philippines
- Novavax seeks emergency use in Europe, Canada
MANILA, Nov 17 (Reuters) – Philippines has approved the emergency use of COVID-19 by Novavax Inc. (NVAX.O), the director of its Food and Drug Administration said on Wednesday, the ninth vaccine approved in Southeast Asia.
The nanoparticle vaccine, brand name Covovax, is manufactured by the Serum Institute of India and is approved for use in adults 18 years of age and older, agency head Rolando Enrique Domingo said at a public news conference.
Covovax, which was 89.7% effective in clinical trials, is given in two doses at least every 21 days, Domingo added.
The Philippines has vaccinated more than a quarter of its 110 million population.
Earlier this month, Novavax received its first emergency license from Indonesia. Novavax also submitted an application for approval of the vaccine in Canada and to the European Medicines Agency.
Reporting: Neil Jerome Morales; Edited by Martin Petty
Our Standards: Thomson Reuters Trust Principles.